THE ROLE OF TOCILIZUMAB IN TREATMENT OF COVID-19
Abstract
Introduction and Aim: COVID-19, especially severe in the elderly, causes symptoms ranging from mild to critical organ failure and death. Treatments have included chloroquine, hydroxychloroquine, and corticosteroids. Tocilizumab, a monoclonal antibody blocking the IL-6 receptor, offers a promising biological therapy by reducing inflammation and possibly lowering thrombosis risk in COVID-19 patients. The aim of this review is to summarize current evidence on tocilizumab’s mechanism and its role in treating SARS-CoV-2 infection.
Material and Methods: A PubMed literature search was conducted using terms: “tocilizumab in COVID-19”, “interleukin-6 in COVID-19”, “interleukin-6 blockade with tocilizumab”, and “COVID-19 and inflammation”. Filters included Free Full Text, Clinical Trial, Randomized Clinical Trial, within the last 10 years.
Results: Studies show that tocilizumab reduces inflammation, shortens hospitalization, and accelerates recovery in COVID-19 patients, especially those with respiratory failure not yet on mechanical ventilation. Additionally, tocilizumab exhibits anticoagulant effects, potentially reducing thrombosis risk.
Conclusion: Originally used for rheumatologic diseases, tocilizumab shows therapeutic potential in COVID-19 by lowering inflammation and reducing mechanical ventilation needs, improving clinical outcomes. However, inconsistent study results highlight the need for further large, well-designed clinical trials to confirm its efficacy and safety.
References
Umakanthan, S., Sahu, P., Ranade, A. V., Bukelo, M. M., Rao, J. S., Abrahao-Machado, L. F., Dahal, S., Kumar, H., & Kv, D. (2020). Origin, transmission, diagnosis and management of coronavirus disease 2019 (COVID-19). Postgraduate medical journal, 96(1142), 753–758. https://doi.org/10.1136/postgradmedj-2020-138234
Khalsa, J. H., Bunt, G., Maggirwar, S. B., & Kottilil, S. (2021). COVID-19 and Cannabidiol (CBD). Journal of addiction medicine, 15(5), 355–356. https://doi.org/10.1097/ADM.0000000000000771
Vallier, J. M., Simon, C., Bronstein, A., Dumont, M., Jobic, A., Paleiron, N., & Mely, L. (2023). Randomized controlled trial of home-based vs. hospital-based pulmonary rehabilitation in post COVID-19 patients. European journal of physical and rehabilitation medicine, 59(1), 103–110. https://doi.org/10.23736/S1973-9087.22.07702-4
Bowen, R., & Arany, P. R. (2023). Use of either transcranial or whole-body photobiomodulation treatments improves COVID-19 brain fog. Journal of biophotonics, 16(8), e202200391. https://doi.org/10.1002/jbio.202200391
RECOVERY Collaborative Group (2024). Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. Child & adolescent health, 8(3), 190–200. https://doi.org/10.1016/S2352-4642(23)00316-4
Wei, Q., Lin, H., Wei, R. G., Chen, N., He, F., Zou, D. H., & Wei, J. R. (2021). Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis. Infectious diseases of poverty, 10(1), 71. https://doi.org/10.1186/s40249-021-00857-w
Karhu, J., Ala-Kokko, T. I., Vuorinen, T., Ohtonen, P., Julkunen, I., & Syrjälä, H. T. (2019). Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. Cytokine, 113, 272–276. https://doi.org/10.1016/j.cyto.2018.07.019
Ge, H. H., Cui, N., Yin, X. H., Hu, L. F., Wang, Z. Y., Yuan, Y. M., Yue, M., Lv, H. D., Wang, Z., Zhang, W. W., Zhang, L., Yuan, L., Fan, X. J., Yang, X., Wu, Y. X., Si, G. Q., Hu, Z. Y., Li, H., Zhang, X. A., Bao, P. T., … Liu, W. (2024). Effect of tocilizumab plus corticosteroid on clinical outcome in patients hospitalized with severe fever with thrombocytopenia syndrome: A randomized clinical trial. The Journal of infection, 89(1), 106181. https://doi.org/10.1016/j.jinf.2024.106181
Chandran, S., Leung, J., Hu, C., Laszik, Z. G., Tang, Q., & Vincenti, F. G. (2021). Interleukin-6 blockade with tocilizumab increases Tregs and reduces T effector cytokines in renal graft inflammation: A randomized controlled trial. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 21(7), 2543–2554. https://doi.org/10.1111/ajt.16459
Rosas, I. O., Bräu, N., Waters, M., Go, R. C., Hunter, B. D., Bhagani, S., Skiest, D., Aziz, M. S., Cooper, N., Douglas, I. S., Savic, S., Youngstein, T., Del Sorbo, L., Cubillo Gracian, A., De La Zerda, D. J., Ustianowski, A., Bao, M., Dimonaco, S., Graham, E., Matharu, B., … Malhotra, A. (2021). Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. The New England journal of medicine, 384(16), 1503–1516. https://doi.org/10.1056/NEJMoa2028700
Rosas IO, Diaz G, Gottlieb RL, et al. A randomized, double-blind, placebo-controlled trial of tocilizumab in hospitalized patients with COVID-19 pneumonia. Clinical Infectious Diseases. 2022;74(3):440–449. doi: 10.1093/cid/ciab781
Salama, C., Han, J., Yau, L., Reiss, W. G., Kramer, B., Neidhart, J. D., Criner, G. J., Kaplan-Lewis, E., Baden, R., Pandit, L., Cameron, M. L., Garcia-Diaz, J., Chávez, V., Mekebeb-Reuter, M., Lima de Menezes, F., Shah, R., González-Lara, M. F., Assman, B., Freedman, J., & Mohan, S. V. (2021). Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. The New England journal of medicine, 384(1), 20–30. https://doi.org/10.1056/NEJMoa2030340
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., Woolley, A. E., Nikiforow, S., Lin, N., Sagar, M., Schrager, H., Huckins, D. S., Axelrod, M., Pincus, M. D., Fleisher, J., Sacks, C. A., … BACC Bay Tocilizumab Trial Investigators (2020). Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. The New England journal of medicine, 383(24), 2333–2344. https://doi.org/10.1056/NEJMoa2028836
Mikulska, M., Nicolini, L. A., Signori, A., Di Biagio, A., Sepulcri, C., Russo, C., Dettori, S., Berruti, M., Sormani, M. P., Giacobbe, D. R., Vena, A., De Maria, A., Dentone, C., Taramasso, L., Mirabella, M., Magnasco, L., Mora, S., Delfino, E., Toscanini, F., Balletto, E., … Bassetti, M. (2020). Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. PloS one, 15(8), e0237831. https://doi.org/10.1371/journal.pone.0237831
REMAP-CAP Investigators, Gordon, A. C., Mouncey, P. R., Al-Beidh, F., Rowan, K. M., Nichol, A. D., Arabi, Y. M., Annane, D., Beane, A., van Bentum-Puijk, W., Berry, L. R., Bhimani, Z., Bonten, M. J. M., Bradbury, C. A., Brunkhorst, F. M., Buzgau, A., Cheng, A. C., Detry, M. A., Duffy, E. J., Estcourt, L. J., … Derde, L. P. G. (2021). Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. The New England journal of medicine, 384(16), 1491–1502. https://doi.org/10.1056/NEJMoa2100433
Patel A, Shah K, Dharsandiya M, et al. IL-6 inhibitors in critically ill COVID-19 patients: a meta-analysis. Journal of Critical Care. 2021;64:75–83. doi: 10.1016/j.jcrc.2021.03.021.
Wang, D., Fu, B., Peng, Z., Yang, D., Han, M., Li, M., Yang, Y., Yang, T., Sun, L., Li, W., Shi, W., Yao, X., Ma, Y., Xu, F., Wang, X., Chen, J., Xia, D., Sun, Y., Dong, L., Wang, J., … Xu, X. (2021). Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Frontiers of medicine, 15(3), 486–494. https://doi.org/10.1007/s11684-020-0824-3
Guaraldi, G., Meschiari, M., Cozzi-Lepri, A., Milic, J., Tonelli, R., Menozzi, M., Franceschini, E., Cuomo, G., Orlando, G., Borghi, V., Santoro, A., Di Gaetano, M., Puzzolante, C., Carli, F., Bedini, A., Corradi, L., Fantini, R., Castaniere, I., Tabbì, L., Girardis, M., … Mussini, C. (2020). Tocilizumab in patients with severe COVID-19: a retrospective cohort study. The Lancet. Rheumatology, 2(8), e474–e484. https://doi.org/10.1016/S2665-9913(20)30173-9
Dastan, F., Saffaei, A., Haseli, S., Marjani, M., Moniri, A., Abtahian, Z., Abedini, A., Kiani, A., Seifi, S., Jammati, H., Hashemian, S. M. R., Pourabdollah Toutkaboni, M., Eslaminejad, A., Heshmatnia, J., Sadeghi, M., Nadji, S. A., Dastan, A., Baghaei, P., Varahram, M., Yousefian, S., … Tabarsi, P. (2020). Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial. International immunopharmacology, 88, 106869. https://doi.org/10.1016/j.intimp.2020.106869
Campochiaro, C., Della-Torre, E., Cavalli, G., De Luca, G., Ripa, M., Boffini, N., Tomelleri, A., Baldissera, E., Rovere-Querini, P., Ruggeri, A., Monti, G., De Cobelli, F., Zangrillo, A., Tresoldi, M., Castagna, A., Dagna, L., & TOCI-RAF Study Group (2020). Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European journal of internal medicine, 76, 43–49. https://doi.org/10.1016/j.ejim.2020.05.021
Almskog, L. M., Sjöström, A., Sundén-Cullberg, J., Taxiarchis, A., Ågren, A., Freyland, S., Börjesson, M., Wikman, A., Wahlgren, C. M., Wanecek, M., van der Linden, J., Antovic, J., Lampa, J., & Magnusson, M. (2024). Tocilizumab reduces hypercoagulation in COVID-19 - Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial. Thrombosis research, 243, 109135. https://doi.org/10.1016/j.thromres.2024.109135
Galván-Román, J. M., Rodríguez-García, S. C., Roy-Vallejo, E., Marcos-Jiménez, A., Sánchez-Alonso, S., Fernández-Díaz, C., Alcaraz-Serna, A., Mateu-Albero, T., Rodríguez-Cortes, P., Sánchez-Cerrillo, I., Esparcia, L., Martínez-Fleta, P., López-Sanz, C., Gabrie, L., Del Campo Guerola, L., Suárez-Fernández, C., Ancochea, J., Canabal, A., Albert, P., Rodríguez-Serrano, D. A., … REINMUN-COVID Group (2021). IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study. The Journal of allergy and clinical immunology, 147(1), 72–80.e8. https://doi.org/10.1016/j.jaci.2020.09.018
Sabbatinelli, J., Giuliani, A., Matacchione, G., Latini, S., Laprovitera, N., Pomponio, G., Ferrarini, A., Svegliati Baroni, S., Pavani, M., Moretti, M., Gabrielli, A., Procopio, A. D., Ferracin, M., Bonafè, M., & Olivieri, F. (2021). Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients. Mechanisms of ageing and development, 193, 111413. https://doi.org/10.1016/j.mad.2020.111413
Broman, N., Feuth, T., Vuorinen, T., Valtonen, M., Hohenthal, U., Löyttyniemi, E., Hirvioja, T., Jalava-Karvinen, P., Marttila, H., Nordberg, M., & Oksi, J. (2022). Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM-a prospective, randomized, single-centre, open-label study. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 28(6), 844–851. https://doi.org/10.1016/j.cmi.2022.02.027
RECOVERY Collaborative Group (2021). Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet (London, England), 397(10285), 1637–1645. https://doi.org/10.1016/S0140-6736(21)00676-0
Perrone, F., Piccirillo, M. C., Ascierto, P. A., Salvarani, C., Parrella, R., Marata, A. M., Popoli, P., Ferraris, L., Marrocco-Trischitta, M. M., Ripamonti, D., Binda, F., Bonfanti, P., Squillace, N., Castelli, F., Muiesan, M. L., Lichtner, M., Calzetti, C., Salerno, N. D., Atripaldi, L., Cascella, M., … TOCIVID-19 investigators, Italy (2020). Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of translational medicine, 18(1), 405. https://doi.org/10.1186/s12967-020-02573-9
Hermine, O., Mariette, X., Tharaux, P. L., Resche-Rigon, M., Porcher, R., Ravaud, P., & CORIMUNO-19 Collaborative Group (2021). Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. JAMA internal medicine, 181(1), 32–40. https://doi.org/10.1001/jamainternmed.2020.6820.
Views:
18
Downloads:
12
Copyright (c) 2025 Aleksandra Gradek, Marcin Sawczuk, Dominika Nowak, Adam Zarzycki, Julia Tarnowska, Filip Szydzik, Bartosz Żegleń, Katarzyna Kozon, Monika Grudzień, Patryk Macuk
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
